Synta Pharmaceuticals to Host Conference Call Today
Call to Discuss Results Presented at ASCO for the Phase 2b
Trial of STA-4783 in Stage IV Metastatic Melanoma
LEXINGTON, Mass.--(BUSINESS WIRE)--June 5, 2007--Synta Pharmaceuticals Corp., (NASDAQ: SNTA) a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced it will hold a conference call at 2:30 p.m. (EST) today to discuss these results, which will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois this morning.
The conference call will be webcast live over the Internet. The webcast can be accessed by logging on to the "Investors" section of Synta Pharmaceuticals' website, www.syntapharma.com, prior to the event.
The call also can be accessed by dialing (877) 407-8035 or (201) 689-8035 prior to the start of the call. The webcast will be archived on the Company's website.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All Synta drug candidates were discovered and developed internally. For more information, please see www.syntapharma.com
CONTACT: Synta Pharmaceuticals Corp. Rob Kloppenburg, 781-541-7125 or MacDougall Biomedical Communications Doug MacDougall, 508-647-0209 SOURCE: Synta Pharmaceuticals Corp.